The prognostic value of decreased miR-101 in various cancers: a meta-analysis of 12 studies

Figures & data

Figure 1 Selection flowchart for the meta-analysis.

Table 1 Baseline characteristics of the 12 studies included

Study	Country	Cancer	n	Specimen	Assay	Cutoff	Negative (%)	HR source	Multivariate analysis	End point	Follow-up (months)	HR (95% CI)	NOS score
Ye et al^Citation11	China	NSCLC	105	Tissue	RT-PCR	Median	49.5	Reported	Yes	OS	NR	1.78 (1.03–3.07)	7
Bao et al^Citation13	China	GBC	53	Tissue	RT-PCR	Median	50.9	SC	No	OS	NR	2.95 (1.32–6.61)	6
Tian et al^Citation15	China	GB	70	Tissue	RT-PCR	Average	50	SC	No	OS	NR	1.67 (0.95–2.97)	6
			70	Tissue	RT-PCR	Average	50	SC	No	PFS	NR	1.54 (0.89–2.65)
Luo et al^Citation12	China	NSCLC	42	Tissue	RT-PCR	≤0.54	47.6	SC	No	OS	NR	1.16 (0.26–5.2)	7
Zheng et al^Citation19	China	HCC	163	Plasma	RT-PCR	≤2.24	46.1	SC	No	OS	NR	3.91 (2.06–7.41)	7
Zhang et al^Citation20	China	HCC	130	Tissue	RT-PCR	Median	42.3	Reported	Yes	OS	103.2	3.27 (1.18–6.92)	7
			130	Tissue	RT-PCR	Median	42.3	Reported	Yes	DFS	103.2	2.56 (1.32–5.69)
Lv et al^Citation22	China	HCC	78	Tissue	RT-PCR	Median	56.4	SC	No	OS	NR	0.63 (0.25–1.24)	7
			78	Tissue	RT-PCR	Median	56.4	SC	No	RFS	NR	0.53 (0.23–1.19)
Li et al^Citation18	China	LSCC	80	Tissue	RT-PCR	Low expression	50	SC	No	OS	NR	1.56 (0.51–4.75)	6
Li et al^Citation16	China	GB	50	Tissue	ISH	Negative expression	82	SC	No	OS	NR	1.12 (0.13–9.67)	6
Zhang et al^Citation17	China	BTCC	72	Tissue	RT-PCR	0.45-fold LTN	36.1	SC	No	OS	NR	2.87 (1.2–6.83)	6
Li et al^Citation14	China	BC	111	Tissue	RT-PCR	Low expression	39.6	SC	No	OS	NR	2.44 (1.05–5.68)	6
			111	Tissue	RT-PCR	Low expression	39.6	SC	No	DFS	NR	2.69 (1.41–5.13)
Slattery et al^Citation21	USA	CRC	1,134	Tissue	RT-PCR	NA	NA	Reported	No	OS	60.4	3.51 (1.72–7.15)	7

Abbreviations: NOS, Newcastle–Ottawa scale; NSCLC, non-small-cell lung cancer; RT-PCR, real-time polymerase chain reaction; OS, overall survival; NR, not reported; GBC, gallbladder cancer; SC, survival curve; GB, glioblastoma; PFS, progression-free survival; HCC, hepatocellular carcinoma; DFS, disease-free survival; RFS, recurrence-free survival; LSCC, laryngeal squamous carcinoma; ISH, in situ hybridization; BTCC, bladder transitional cell carcinoma; LTN, lower than normal; BC, breast cancer; CRC, colorectal cancer; CI, confidence interval; NA, not available; HR, hazard ratio.

Table 2 Meta-analysis results of associations of decreased miR-101 expression with clinicopathological parameters

Clinicopathological parameters	References	Meta-analysis	OR (95% CI)	P-value
Tumor differentiation (poor/moderate–well)	^Citation11^–^Citation13, ^Citation15^–^Citation17, ^Citation19, ^Citation20	Random	2.17 (1.14–4.13)	0.019
Tumor classification (T3–T4/T1–T2)	^Citation11^–^Citation13, ^Citation17, ^Citation20	Fixed	5.25 (3.39–8.12)	<0.001
Lymph node classification (N1–N3/N0)	^Citation11^–^Citation13, ^Citation17	Random	2.42 (0.56–10.49)	0.239
TNM stage (III–IV/I–II)	^Citation11, ^Citation13, ^Citation19	Fixed	6.18 (3.79–10.09)	<0.001

Abbreviation: OR, odds ratio.

Figure 2 Forest plot of studies evaluating HRs of decreased miR-101 expression for OS.

Abbreviations: HRs, hazard ratios; OS, overall survival.

Table 3 Subgroup analysis of decreased miR-101 for OS in solid tumors

	Studies	Model	HR (95% CI)	Heterogeneity
				I^2 (%)	P-value
Ethnicity
Asian	11	Fixed	2.04 (1.6–2.59)	40.1	0.082
Non-Asian	1	–	3.51 (1.72–7.15)	–	–
Cancer type
NSCLC	2	Fixed	1.69 (1.01–2.83)	0	0.599
HCC	3	Random	2.18 (1.41–3.37)	84.9	0.001
GB	2	Fixed	1.63 (0.94–2.82)	0	0.816
Specimen
Tissue	11	Fixed	1.97 (1.55–2.52)	33	0.137
Serum	1	–	3.91 (2.06–7.42)	–	–
Assay
qRT-PCR	11	Random	2.17 (1.72–2.72)	45.5	0.049
ISH	1	–	1.12 (0.13–9.67)	–	–
Sample size
>100	5	Fixed	2.65 (1.93–3.65)	22.2	0.273
<100	7	Fixed	1.73 (1.25–2.39)	41.1	0.117
HR estimated
SC	9	Fixed	2.01 (1.52–2.66)	47.8	0.053
Reported	3	Fixed	2.45 (1.66–3.62)	26	0.259
Analysis method
Univariate	10	Random	2.11 (1.67–2.81)	48.2	0.043
Multivariate	2	Fixed	2.17 (1.32–3.35)	24	0.251

Abbreviations: OS, overall survival; NSCLC, non-small-cell lung carcinoma; HCC, hepatocellular carcinoma; GB, glioblastoma; qRT-PCR, quantitative real-time polymerase chain reaction; ISH, in situ hybridization; SC, survival curve; HR, hazard ratio; OS, overall survival.

Figure 3 Forest plot of studies evaluating HRs of decreased miR-101 expression for DFS/RFS/PFS.

Note: Weights are from random effects analysis.
Abbreviations: DFS, disease-free survival; RFS, recurrence-free survival; PFS, progression-free survival; HR, hazard ratio; OS, overall survival.

Figure 4 Begg funnel plot for publication-bias test of overall survival.

Abbreviations: HR, hazard ratio; SE, standard error.

Figure 5 Sensitivity analysis of relationship between decreased miR-101 expression and overall survival in cancers.

Table 4 Gene targets of miR-101 in this meta-analysis

Study	Type of cancer	Gene target
Zhang et al^Citation38	Non-small-cell lung cancer	EZH2
Jiang et al^Citation39	Osteosarcoma	ROCK1
Hui et al^Citation40	Oral squamous-cell carcinoma	CXCR7
Konno et al^Citation41	Endometrial cancer	EZH2, MCL1, FOS
Lin et al^Citation42	Thyroid carcinoma	RAC1
Liu et al^Citation43	Ovarian cancer	EZH2
Sun et al^Citation44	Nasopharyngeal carcinoma	STMN1

YeZYinSSuZDownregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2Oncotarget2016725375243753527229528

 PubMedGoogle Scholar

BaoRFShuYJHuYPmiR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinomaOncotarget2016716223392235426968949

 PubMedGoogle Scholar

TianTMingyiMQiuXQiuYMicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastomaOncotarget2016748795847959527792996

 PubMedGoogle Scholar

LuoLZhangTLiuHMiR-101 and Mcl-1 in non-small cell lung cancer: expression profile and clinical significanceMed Oncol20122931681168621993632

 PubMedGoogle Scholar

ZhengFLiaoYJCaiMYSystemic delivery of microRNA-101 potently inhibits hepatocellular carcinoma in vivo by repressing multiple targetsPLoS Genet2015112e100487325693145

 PubMed Web of Science ®Google Scholar

ZhangYGuoXXiongLMicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinomaFEBS Lett2012586244362437023178713

 PubMed Web of Science ®Google Scholar

LvXLiJYangBClinical effects of miR-101 on prognosis of hepa-tocellular carcinoma and carcinogenic mechanism of anti-miR-101Oncol Rep20163642184219227498785

 PubMedGoogle Scholar

LiMTianLRenHMicroRNA-101 is a potential prognostic indicator of laryngeal squamous cell carcinoma and modulates CDK8J Transl Med20151327126286725

 PubMedGoogle Scholar

LiXPYuanZBLiuWJCPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in gliomaCell Death Dis20134e67523788032

 PubMedGoogle Scholar

ZhangHQiFCaoYChenMZuXDown-regulated microRNA-101 in bladder transitional cell carcinoma is associated with poor prognosisMed Sci Monit20142081281724834983

 PubMedGoogle Scholar

LiJTJiaLTLiuNNMiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7Oncotarget2015631308183083026360780

 PubMedGoogle Scholar

SlatteryMLHerrickJSPellattDFSite-specific associations between miRNA expression and survival in colorectal cancer casesOncotarget2016737601936020527517623

 PubMedGoogle Scholar

ZhangJGGuoJFLiuDLLiuQWangJJMicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of Zeste homolog 2J Thorac Oncol20116467167821270667

 PubMed Web of Science ®Google Scholar

JiangRZhangCLiuGGuRWuHMicroRNA-101 inhibits proliferation, migration and invasion in osteosarcoma cells by targeting ROCK1Am J Cancer Res201771889728123850

 PubMed Web of Science ®Google Scholar

HuiYLiYJingYFengJQDingYmiRNA-101 acts as a tumor suppressor in oral squamous cell carcinoma by targeting CX chemokine receptor 7Am J Transl Res20168114902491127904690

 PubMed Web of Science ®Google Scholar

KonnoYDongPXiongYMicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cellsOncotarget20145156049606225153722

 PubMedGoogle Scholar

LinXGuanHLiHmiR-101 inhibits cell proliferation by targeting Rac1 in papillary thyroid carcinomaBiomed Rep20142112212624649082

 PubMedGoogle Scholar

LiuLGuoJYuLmiR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancerTumour Biol20143512126191262625260883

 PubMed Web of Science ®Google Scholar

SunQLiuTZhangTMiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1Mol Med Rep20151153330333625607713

 PubMed Web of Science ®Google Scholar